Rayence Co

Rayence Co R&D Expenses

The Research & Development Expenses of Rayence Co (228850.KQ) as of Nov 7, 2026 is 14.70 B KRW. In the previous year, Research & Development Expenses was 13.73 B KRW — a change of 7.04% (higher).

R&D Expenses

14.70 BKRW

YoY

7.04%

Last updated:

Research & Development Expenses of Rayence Co is 2025 14.70 B KRW. Research & Development Expenses of Rayence Co was 2024 13.73 B KRW. It decreases by 7.04% higher compared to the previous year.

The Rayence Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2016
10.59 B KRW
Jan 1, 2017
8.51 B KRW
Jan 1, 2020
4.78 B KRW
Jan 1, 2021
8.17 B KRW
Jan 1, 2022
9.33 B KRW
Jan 1, 2023
10.79 B KRW
Jan 1, 2024
13.73 B KRW
Jan 1, 2025
14.70 B KRW
The Rayence Co R&D Expenses history
YEARR&D ExpensesYoY
14.70 BKRW+7.04%
13.73 BKRW+27.21%
10.79 BKRW+15.74%
9.33 BKRW+14.14%
8.17 BKRW+70.78%
4.78 BKRW-43.75%
8.51 BKRW-19.70%
10.59 BKRW+99.87%
5.30 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Research & Development Expenses of Rayence Co is 14.70 B KRW in 2025.

Research & Development Expenses of Rayence Co changed from 13.73 B KRW to 14.70 B KRW, representing a 7.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Rayence Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Rayence Co

All Key Metrics — Rayence Co